<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical use of tissue-type plasminogen activator (tPA) in the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> is profoundly constrained by its serious side effects </plain></SENT>
<SENT sid="1" pm="."><plain>We report that the deleterious effects of tPA on <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> and <z:mp ids='MP_0001915'>intracranial bleeding</z:mp> are separable from its fibrinolytic activity and can be neutralized </plain></SENT>
<SENT sid="2" pm="."><plain>A hexapeptide (EEIIMD) corresponding to amino acids 350-355 of plasminogen activator inhibitor type 1 (PAI-1) abolished the tPA-induced increase in <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:mp ids='MP_0001915'>intracranial bleeding</z:mp> in both mechanical and embolic models of <z:hpo ids='HP_0001297'>stroke</z:hpo> in rats, and reduced <z:hpo ids='HP_0002181'>brain edema</z:hpo> and <z:hpo ids='HP_0002529'>neuronal loss</z:hpo> after traumatic brain injury in pigs </plain></SENT>
<SENT sid="3" pm="."><plain>These experiments suggest mechanisms to reduce the neurotoxic effects of tPA without compromising its fibrinolytic activity, through the use of selective <z:chebi fb="68" ids="48706">antagonists</z:chebi> and new tPA formulations </plain></SENT>
</text></document>